Press Releases
We’re Delivering the Promise of Healthier Lives.
CURE PHARMACEUTICAL
Press Releases
We specialize in optimal formulations to achieve targeted release and exposure of medications.
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
OXNARD, Calif., Aug. 09, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive...
CURE Pharmaceutical Announces the Appointment of New Board Member
Gerald Bagg brings deep understanding of CPG to CUREOXNARD, Calif., Aug. 02, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary platform technology company, today announced the appointment of Gerald Bagg to its board of directors. This...
CURE Pharmaceutical Announces Teleconference With Investors
Updates on Recent Transaction and Business will be Provided OXNARD, Calif., Aug. 01, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary platform technology company, today announced that the Company will be hosting a teleconference...
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
Proceeds Will Be Used to Grow CURE's Wellness and Beauty Brands and Its Remaining Proprietary Platform TechnologyOXNARD, Calif., July 28, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary platform technology company, today announced that it...
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)
CURE's Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD)CCHMC to Seek Formulary...
Sera Labs Inc. Products Now Available at Walmart, Bed Bath & Beyond, CVS and Target.com
LOS ANGELES, April 14, 2022 -- Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond stores. Sera Labs...
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico
COFEPRIS (Mexico's equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE's Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE's patented Oral Thin Film (OTF) dose form CUREform™OXNARD,...
Sera Labs, a Subsidiary of CURE Pharmaceutical, Consummates Exclusive International Distribution Agreement With Leading Canadian Distributor
Northern Response International To Distribute Seratopical Revolution® Masstige LineLOS ANGELES and TORONTO, Dec. 09, 2021 -- The Sera Labs, a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR) today announced its global expansion into Canada by...
CURE Pharmaceutical Receives Patent Approval for Its CUREfilm Blue™ Technology
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue...
CURE Pharmaceutical Reports Second Quarter 2021 Revenue Rose Nearly 700% Driven by Sales from Sera Labs Product Lines
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced results for the quarter ended June 30, 2021, including the following highlights: Revenue of $2.1 million reflected an increase of nearly 700% from a year ago Gross profit rose 676% to...
Seratopical Revolution Skincare Line by The Sera Labs Inc., a CURE Pharmaceutical Company, will be Available for Purchase this Fall at CVS, one of the Leading National Drug Store Chains
LOS ANGELES - Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced that all six facial products of the Seratopical Revolution skincare line will be available for purchase at CVS in the Fall of 2021. CVS is one of the leading...
CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer Jonathan...
CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company, (BRC), an active Drug Enforcement...
Nicole Kidman and Sera Labs Inc., a CURE Pharmaceutical Company, Launch Seratopical Revolution and New Ad Campaign
The plant based, alcohol-free, non-CBD, anti-aging beauty line is available Wednesday, June 9 LOS ANGELES - Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today a new ad campaign and launch of Seratopical Revolution, a new clean,...
CURE Pharmaceutical Schedules Investor Webcast for Thursday, May 27, 2021
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time. Rob...
CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021. First Quarter 2021 and...
CURE Pharmaceutical Receives ISO Certification for Laboratory and Manufacturing Facility
LOS ANGELES - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification...
Nicole Kidman, Sera Labs Strategic Business Partner/Global Brand Ambassador and Nancy Duitch, Sera Labs Founder/CEO Headline Collision 2021 and Talk the Future of Beauty Technology
InStyle Magazine's Editor in Chief and Host of Ladies First, Laura Brown Moderated the Intimate ConversationLOS ANGELES - Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), headlined Collision 2021 and discussed the changing landscape of beauty,...
CURE Pharmaceutical Announces Successful Results From Initial Clinical Trials for Erectile Dysfunction Product CUREfilm Blue™
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies....
CURE Pharmaceutical to Present at the 2021 Sequire Cannabis Conference on Tuesday, April 20, at 2 p.m. EDT/11 a.m. PDT
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that Rob Davidson, CURE's Chief Executive Officer, and Nancy Duitch, CEO of subsidiary Sera Labs and Chief Strategic...
Nicole Kidman, Sera Labs Strategic Business Partner/Global Brand Ambassador and Nancy Duitch, Sera Labs Founder/CEO Headline Collision 2021
LOS ANGELES--(BUSINESS WIRE)--Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today that Academy Award, Golden Globe and Emmy Award-winning actor/producer/entrepreneur Nicole Kidman and Sera Labs CEO/CURE Pharmaceutical Chief...
CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020
Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary...
CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds...
CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding...
CURE Pharmaceutical’s Subsidiary Sera Labs Launches National Television, Radio & Digital Advertising Campaign for Nutri-Strips Sleep A.S.A.P.
Sleep A.S.A.P. provides proof of concept and monetization for CURE's patented oral thin-film technology LOS ANGELES & OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a technology focused, vertically integrated drug...